Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3099830rdf:typepubmed:Citationlld:pubmed
pubmed-article:3099830lifeskim:mentionsumls-concept:C0392918lld:lifeskim
pubmed-article:3099830lifeskim:mentionsumls-concept:C0205145lld:lifeskim
pubmed-article:3099830lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:3099830lifeskim:mentionsumls-concept:C0024337lld:lifeskim
pubmed-article:3099830lifeskim:mentionsumls-concept:C0032140lld:lifeskim
pubmed-article:3099830lifeskim:mentionsumls-concept:C0005456lld:lifeskim
pubmed-article:3099830lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:3099830lifeskim:mentionsumls-concept:C0182400lld:lifeskim
pubmed-article:3099830lifeskim:mentionsumls-concept:C1704788lld:lifeskim
pubmed-article:3099830lifeskim:mentionsumls-concept:C1522605lld:lifeskim
pubmed-article:3099830pubmed:issue22lld:pubmed
pubmed-article:3099830pubmed:dateCreated1987-2-27lld:pubmed
pubmed-article:3099830pubmed:abstractTextAn antibody population that reacted with the high-affinity lysine binding site of human plasminogen was elicited by immunizing rabbits with an elastase degradation product containing kringles 1-3 (EDP I). This antibody was immunopurified by affinity chromatography on plasminogen-Sepharose and elution with 0.2 M 6-aminohexanoic acid. The eluted antibodies bound [125I]EDP I, [125I]Glu-plasminogen, and [125I]Lys-plasminogen in radioimmunoassays, and binding of each ligand was at least 99% inhibited by 0.2 M 6-aminohexanoic acid. The concentrations for 50% inhibition of [125I]EDP I binding by tranexamic acid, 6-aminohexanoic acid, and lysine were 2.6, 46, and 1730 microM, respectively. Similar values were obtained with plasminogen and suggested that an unoccupied high-affinity lysine binding site was required for antibody recognition. The antiserum reacted exclusively with plasminogen derivatives containing the EDP I region (EDP I, Glu-plasminogen, Lys-plasminogen, and the plasmin heavy chain) and did not react with those lacking an EDP I region [miniplasminogen, the plasmin light chain or EDP II (kringle 4)] or with tissue plasminogen activator or prothrombin, which also contain kringles. By immunoblotting analyses, a chymotryptic degradation product of Mr 20,000 was derived from EDP I that retained reactivity with the antibody. The high-affinity lysine binding site was equally available to the antibody probe in Glu- and Lys-plasminogen and also appeared to be unoccupied in the plasmin-alpha 2-antiplasmin complex. alpha 2-Antiplasmin inhibited the binding of radiolabeled EDP I, Glu-plasminogen, or Lys-plasminogen by the antiserum, suggesting that the recognized site is involved in the noncovalent interaction of the inhibitor with plasminogen.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:3099830pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3099830pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3099830pubmed:languageenglld:pubmed
pubmed-article:3099830pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3099830pubmed:citationSubsetIMlld:pubmed
pubmed-article:3099830pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3099830pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3099830pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3099830pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3099830pubmed:statusMEDLINElld:pubmed
pubmed-article:3099830pubmed:monthNovlld:pubmed
pubmed-article:3099830pubmed:issn0006-2960lld:pubmed
pubmed-article:3099830pubmed:authorpubmed-author:PlowE FEFlld:pubmed
pubmed-article:3099830pubmed:authorpubmed-author:MilesL ALAlld:pubmed
pubmed-article:3099830pubmed:issnTypePrintlld:pubmed
pubmed-article:3099830pubmed:day4lld:pubmed
pubmed-article:3099830pubmed:volume25lld:pubmed
pubmed-article:3099830pubmed:ownerNLMlld:pubmed
pubmed-article:3099830pubmed:authorsCompleteYlld:pubmed
pubmed-article:3099830pubmed:pagination6926-33lld:pubmed
pubmed-article:3099830pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:3099830pubmed:meshHeadingpubmed-meshheading:3099830-...lld:pubmed
pubmed-article:3099830pubmed:meshHeadingpubmed-meshheading:3099830-...lld:pubmed
pubmed-article:3099830pubmed:meshHeadingpubmed-meshheading:3099830-...lld:pubmed
pubmed-article:3099830pubmed:meshHeadingpubmed-meshheading:3099830-...lld:pubmed
pubmed-article:3099830pubmed:meshHeadingpubmed-meshheading:3099830-...lld:pubmed
pubmed-article:3099830pubmed:meshHeadingpubmed-meshheading:3099830-...lld:pubmed
pubmed-article:3099830pubmed:meshHeadingpubmed-meshheading:3099830-...lld:pubmed
pubmed-article:3099830pubmed:meshHeadingpubmed-meshheading:3099830-...lld:pubmed
pubmed-article:3099830pubmed:meshHeadingpubmed-meshheading:3099830-...lld:pubmed
pubmed-article:3099830pubmed:year1986lld:pubmed
pubmed-article:3099830pubmed:articleTitleTopography of the high-affinity lysine binding site of plasminogen as defined with a specific antibody probe.lld:pubmed
pubmed-article:3099830pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3099830pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3099830lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3099830lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3099830lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3099830lld:pubmed